Humana (HUM) Stock Price, News & Analysis

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last twelve months. There are currently 10 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.
View HUM analyst ratings or view top-rated stocks.

19 brokerages have issued twelve-month target prices for Humana's shares. Their HUM share price targets range from $310.00 to $630.00. On average, they expect the company's stock price to reach $465.42 in the next year. This suggests a possible upside of 43.9% from the stock's current price.
View analysts price targets for HUM or view top-rated stocks among Wall Street analysts.

Humana's stock was trading at $457.81 at the beginning of 2024. Since then, HUM stock has decreased by 29.3% and is now trading at $323.46.
View the best growth stocks for 2024 here.

Humana saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,570,000 shares, an increase of 14.7% from the February 29th total of 2,240,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is presently 1.3 days. Currently, 2.1% of the shares of the stock are short sold.
View Humana's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our HUM earnings forecast.

Humana will be holding an earnings conference call on Wednesday, April 24th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Humana Inc. (NYSE:HUM) announced its earnings results on Thursday, January, 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by $0.87. The insurance provider earned $26.46 billion during the quarter, compared to analyst estimates of $25.47 billion. Humana had a net margin of 2.34% and a trailing twelve-month return on equity of 19.44%. The firm's revenue was up 17.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 EPS.
Read the conference call transcript.

Humana declared a quarterly dividend on Thursday, February 15th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.885 per share on Friday, April 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Wednesday, March 27th.
Read our dividend analysis for HUM.

Humana (NYSE:HUM) pays an annual dividend of $3.54 per share and currently has a dividend yield of 1.13%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 17.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HUM will have a dividend payout ratio of 15.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HUM.

ETFs with the largest weight of Humana (NYSE:HUM) stock in their portfolio include Optimize AI Smart Sentiment Event-Driven ETF (OAIE), iShares U.S. Healthcare Providers ETF (IHF), Harbor Health Care ETF (MEDI), First Trust Long/Short Equity ETF (FTLS), Alpha Intelligent - Large Cap Value ETF (AILV), Janus Henderson US Sustainable Equity ETF (SSPX), First Trust Growth Strength ETF (FTGS) and American Customer Satisfaction ETF (ACSI).

Humana issued an update on its FY 2024 earnings guidance on Saturday, March, 16th. The company provided earnings per share (EPS) guidance of 16.000-16.000 for the period, compared to the consensus EPS estimate of 16.380. The company issued revenue guidance of -.

1,597 employees have rated Humana Chief Executive Officer Bruce D. Broussard on Glassdoor.com. Bruce D. Broussard has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA), Boeing (BA), Salesforce (CRM), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM).

Humana's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perpetual Ltd (0.09%), Los Angeles Capital Management LLC (0.02%), Czech National Bank (0.02%), Artemis Investment Management LLP (0.02%), Global Assets Advisory LLC (0.01%) and Alaska Permanent Fund Corp (0.01%). Insiders that own company stock include Bruce D Broussard, Christopher H Hunter, David A Jr/Ky Jones, Jorge S Mesquita, Joseph C Ventura, Samir Deshpande, Susan M Diamond, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming.
View institutional ownership trends.

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.